Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track TRDA with free AI briefings, catalyst countdowns, and dilution alerts.

TRDA · Entrada Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$193M Cash on Hand
18.6mo Cash Runway
Follow TRDA by email Get an email when TRDA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about TRDA, unsubscribe in one click. Privacy

📣 What TRDA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
ENTR-601-44 Duchenne Muscular Dystrophy (DMD) Phase 1/2 · NCT07037862 Recruiting
ENTR-601-45 Duchenne Muscular Dystrophy (DMD) Phase 1/2 · NCT07038824 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

TRDA holds $193M in cash and short-term investments (as of Sep 30, 2026) and burns about $31.2M/quarter from operations, an estimated runway of 18.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 48 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TRDA files for a raise →

👥 Who Owns TRDA

Insiders 44.2% Other 5%+ holders 9.9% Institutions (184 holders) 45.9% Public and other holders 0%
HolderTypeShares% of sharesAs of
BAKER BROS. ADVISORS LP
10% owner
Insider 4,691,392 11.98% 2025-11-20
MPM BIOVENTURES 2018, L.P.
10% owner
Insider 3,885,115 9.92% 2026-09-04
MPM BioVentures 2014, L.P.
10% owner
Includes shares also reported by MPM BIOVENTURES 2018, L.P., counted once
Insider 3,885,115 9.92% 2026-09-04
ANSBERT GADICKE 5%+ holder (13D) 3,885,115 9.92% 2026-09-08
5AM Ventures V, L.P.
10% owner
Insider 3,877,094 9.90% 2026-08-06
Kush Parmar
Director · +19,000 options
Insider 3,784,650 9.67% 2026-08-06
Dipal Doshi
CEO, Director · +208,000 options
Insider 517,290 1.32% 2026-09-02
Natarajan Sethuraman
President, Research & Develop. · +83,200 options
Insider 214,238 0.55% 2026-09-02
Nathan J Dowden
President & COO · +133,031 options
Insider 196,060 0.50% 2026-09-02
Kory James Wentworth
Chief Financial Officer · +66,600 options
Insider 117,277 0.30% 2026-09-02
Bernhardt G Zeiher
Director · +19,000 options
Insider 5,000 0.01% 2026-05-20

Share count 39,150,334 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full TRDA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TRDA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.